Tirzepatide Alcohol Outcomes Study (TAOS)

Purpose

This clinical trial is investigating the effects of a GLP-1-based medication, tirzepatide, on alcohol-related outcomes in adults seeking to reduce or quit drinking.

Keywords: Alcohol, addiction, substance use, overweight, obesity, treatment, tirzepatide, GLP-1

Study Sites

University of Southern California Health Sciences Campus, Los Angeles, California 90033

 
  • Men & Women
Age icon
21 - 65
 
 

To find out if you are eligible please email barlab@usc.edu.

Study contact: Tom Gilmore, (213) 962-0698.

 

What's involved?

Study length

  • 12 Weeks

Number of visits

  • NA

Prescription
    None
Procedures
Compensation

  • Contact the study team to find out more.

Medical cost coverage
    None

Study Team

Photohandler
Principal Investigator
Christian Hendershot, PhD

For questions about this study, contact:

We respect your privacy!

All the information you give us is stored in a secure, password protected database. All the information that you choose to share will be kept private and confidential. Read University of Southern California's Privacy Policy here.